Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day

BROOMFIELD, Colo., Oct. 24, 2011 /PRNewswire/ -- Accera, Inc., a biotech company specializing in cognitive health, announced today the company has donated $50,000 to the Alzheimer's Foundation of America (AFA) for sponsorship of its "National Memory Screening Day" (NMSD) during National Alzheimer's Disease Awareness Month.  These funds will be used to further the AFA's efforts to educate and support individuals with Alzheimer's disease (AD) and their families, especially about the importance of early detection of memory problems.

Eric J. Hall, founding president and CEO of AFA, said, "We're grateful that despite the difficult economy, Accera continues to demonstrate its generous commitment to individuals and their families facing Alzheimer's disease now or in the future.  It's a public health crisis that requires corporate engagement."

NMSD, an annual initiative sponsored by AFA, provides free, confidential, memory screenings to individuals concerned about memory loss with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation on November 15.

Samuel Henderson, Ph.D., vice president of research and development for Accera, stated, "On behalf of the Accera team, we're happy to contribute to AFA's ongoing efforts of helping those affected by Alzheimer's and raise awareness about the options available to patients and their caregivers."  He continued, "It's our hope that through continued awareness initiatives such as NMSD, we can better educate patients and their families about this devastating disease."

About Alzheimer's disease
AD significantly impacts millions of family members and other caregivers – mentally, physically and financially.  The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week.  With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Axona®
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells.  With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.  For more information about Axona, please visit www.about-axona.com or contact a doctor who is familiar with the product.

About Accera, Inc.  
Accera, Inc. is a privately held commercial-stage cognitive health company that developed and now markets Axona in the US.  Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease.  In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients.  Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease.  Accera engages in research, development and commercialization of other clinical applications for Axona.

For more information about Accera, please visit www.accerapharma.com.

SOURCE Accera, Inc.